Trials / Withdrawn

WithdrawnNCT00175851

Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy

An Open-label, Multicenter, Follow-up Trial to Evaluate the Long-term Safety and Efficacy of Seletracetam Used as Adjunctive Treatment Using a Flexible Dosing Scheme of 4 to 80 mg b.i.d. in Subjects Aged 16 Years or Older Suffering From Epilepsy

Status: Withdrawn
Phase: Phase 3
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: UCB Pharma · Industry
Sex: All
Age: 16 Years
Healthy volunteers: —

Summary

This is a safety and efficacy study of add-on therapy with seletracetam in epilepsy patients who have participated in a previous seletracetam study

Conditions

Epilepsy

Interventions

Type	Name	Description
DRUG	Seletracetam (ucb 44212)

Timeline

Start date: 2008-05-01
First posted: 2005-09-15
Last updated: 2012-05-28

Source: ClinicalTrials.gov record NCT00175851. Inclusion in this directory is not an endorsement.